Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336387 · ClinicalTrials.gov registry record · Phase 1
Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01336387: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01336387 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01336387, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects and the best dose of retinoid 9cUAB30 in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of retinoid 9cUAB30 may keep cancer from forming.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- OTHER pharmacological study
- OTHER cancer prevention
- DRUG retinoid 9cUAB30
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336387
The ClinicalTrials.gov registry entry for NCT01336387 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01336387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336387 about?
NCT01336387 is a clinical study titled "Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers". This randomized phase I trial studies the side effects and the best dose of retinoid 9cUAB30 in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of retinoid 9cUAB30 may keep cancer from forming.
What is the current status of trial NCT01336387?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2011-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01336387?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), pharmacological study (OTHER), cancer prevention (OTHER), retinoid 9cUAB30 (DRUG).
Who is sponsoring clinical trial NCT01336387?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.